OACC vs BFLY vs EXAS vs RLAY vs GH

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus 17. 7% for Exact Sciences Corporation (EXAS). Oaktree Acquisition Corp. III Life Sciences (OACC) offers the better valuation at 197. 4x trailing P/E, making it the more compelling value choice. Analysts rate Butterfly Network, Inc. (BFLY) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oaktree Acquisition Corp.

III Life Sciences (OACC) delivered a total return of +7. 0%, compared to -62. 9% for Butterfly Network, Inc. (BFLY). Over 10 years, the gap is even starker: EXAS returned +1669% versus RLAY's -63. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Butterfly Network, Inc. 's 3. 23β — meaning BFLY is approximately 6042% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus 17. 7% for Exact Sciences Corporation (EXAS). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to 6. 7% for Guardant Health, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Oaktree Acquisition Corp.

III Life Sciences (OACC) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OACC leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RLAY: 69.

3% to $21. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Butterfly Network, Inc. (BFLY) carries a higher beta of 3. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, BFLY: -58. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OACC (Financial Services) and BFLY (Healthcare) and EXAS (Healthcare) and RLAY (Healthcare) and GH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OACC is a small-cap quality compounder stock; BFLY is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; RLAY is a small-cap high-growth stock; GH is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.